12-56100939-CAAAAAAAAAAAAAAAA-CAAAAAAAAAAAAAAAAAA
Variant summary
Our verdict is Likely benign. The variant received -4 ACMG points: 0P and 4B. BS1
The NM_001982.4(ERBB3):c.3202-98_3202-97dupAA variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00954 in 298,222 control chromosomes in the GnomAD database, with no homozygous occurrence. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.015 ( 0 hom., cov: 0)
Exomes 𝑓: 0.0084 ( 0 hom. )
Consequence
ERBB3
NM_001982.4 intron
NM_001982.4 intron
Scores
Not classified
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.0110
Publications
1 publications found
Genes affected
ERBB3 (HGNC:3431): (erb-b2 receptor tyrosine kinase 3) This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized. [provided by RefSeq, Jul 2008]
ERBB3 Gene-Disease associations (from GenCC):
- lethal congenital contracture syndrome 2Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
- visceral neuropathy, familial, 1, autosomal recessiveInheritance: AR Classification: STRONG Submitted by: G2P
- Hirschsprung diseaseInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Likely_benign. The variant received -4 ACMG points.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.015 (747/49646) while in subpopulation AFR AF = 0.0174 (185/10662). AF 95% confidence interval is 0.0153. There are 0 homozygotes in GnomAd4. There are 298 alleles in the male GnomAd4 subpopulation. Median coverage is 0. This position passed quality control check.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| ERBB3 | NM_001982.4 | c.3202-98_3202-97dupAA | intron_variant | Intron 26 of 27 | ENST00000267101.8 | NP_001973.2 | ||
| ERBB3 | XM_047428500.1 | c.3025-98_3025-97dupAA | intron_variant | Intron 26 of 27 | XP_047284456.1 | |||
| ERBB3 | XM_047428501.1 | c.3025-98_3025-97dupAA | intron_variant | Intron 26 of 27 | XP_047284457.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0150 AC: 747AN: 49652Hom.: 0 Cov.: 0 show subpopulations
GnomAD3 genomes
AF:
AC:
747
AN:
49652
Hom.:
Cov.:
0
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00844 AC: 2099AN: 248576Hom.: 0 AF XY: 0.00831 AC XY: 1153AN XY: 138794 show subpopulations ⚠️ The allele balance in gnomAD version 4 Exomes is significantly skewed from the expected value of 0.5.
GnomAD4 exome
AF:
AC:
2099
AN:
248576
Hom.:
AF XY:
AC XY:
1153
AN XY:
138794
show subpopulations
⚠️ The allele balance in gnomAD version 4 Exomes is significantly skewed from the expected value of 0.5.
African (AFR)
AF:
AC:
85
AN:
5880
American (AMR)
AF:
AC:
102
AN:
14228
Ashkenazi Jewish (ASJ)
AF:
AC:
51
AN:
7408
East Asian (EAS)
AF:
AC:
69
AN:
10648
South Asian (SAS)
AF:
AC:
281
AN:
43178
European-Finnish (FIN)
AF:
AC:
72
AN:
11054
Middle Eastern (MID)
AF:
AC:
7
AN:
818
European-Non Finnish (NFE)
AF:
AC:
1341
AN:
143424
Other (OTH)
AF:
AC:
91
AN:
11938
⚠️ The allele balance in gnomAD4 Exomes is highly skewed from 0.5 (p-value = 0.000000), which strongly suggests a high chance of mosaicism in these individuals.
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.267
Heterozygous variant carriers
0
220
441
661
882
1102
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.0150 AC: 747AN: 49646Hom.: 0 Cov.: 0 AF XY: 0.0137 AC XY: 298AN XY: 21742 show subpopulations
GnomAD4 genome
AF:
AC:
747
AN:
49646
Hom.:
Cov.:
0
AF XY:
AC XY:
298
AN XY:
21742
show subpopulations
African (AFR)
AF:
AC:
185
AN:
10662
American (AMR)
AF:
AC:
26
AN:
3784
Ashkenazi Jewish (ASJ)
AF:
AC:
26
AN:
1602
East Asian (EAS)
AF:
AC:
16
AN:
1514
South Asian (SAS)
AF:
AC:
6
AN:
996
European-Finnish (FIN)
AF:
AC:
4
AN:
626
Middle Eastern (MID)
AF:
AC:
0
AN:
72
European-Non Finnish (NFE)
AF:
AC:
470
AN:
29272
Other (OTH)
AF:
AC:
5
AN:
684
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.411
Heterozygous variant carriers
0
27
55
82
110
137
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
PhyloP100
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.